294 related articles for article (PubMed ID: 10720524)
61. [Cellular and acellular anti-pertussis vaccines].
Locht C
Ann Pharm Fr; 2001 May; 59(3):198-205. PubMed ID: 11427821
[TBL] [Abstract][Full Text] [Related]
62. Differences of humoral and cellular immune response to an acellular pertussis booster in adolescents with a whole cell or acellular primary vaccination.
Rieber N; Graf A; Belohradsky BH; Hartl D; Urschel S; Riffelmann M; Wirsing von König CH; Liese J
Vaccine; 2008 Dec; 26(52):6929-35. PubMed ID: 18852002
[TBL] [Abstract][Full Text] [Related]
63. Population-based incidence of pertussis among adolescents and adults, Minnesota, 1995-1996.
Strebel P; Nordin J; Edwards K; Hunt J; Besser J; Burns S; Amundson G; Baughman A; Wattigney W
J Infect Dis; 2001 May; 183(9):1353-9. PubMed ID: 11294666
[TBL] [Abstract][Full Text] [Related]
64. [Evaluation of the usefulness of Bordetella pertussis toxins for serodiagnosis of whooping cough].
Chodorowska M; Kuklińska D
Med Dosw Mikrobiol; 1998; 50(1-2):89-95. PubMed ID: 9857618
[TBL] [Abstract][Full Text] [Related]
65. Immunoglobulin E response to pertussis toxin in whooping cough and after immunization with a whole-cell and an acellular pertussis vaccine.
Hedenskog S; Björkstén B; Blennow M; Granström G; Granström M
Int Arch Allergy Appl Immunol; 1989; 89(2-3):156-61. PubMed ID: 2759713
[TBL] [Abstract][Full Text] [Related]
66. [An observation on immunization reaction and serological effect of adsorbed purified pertussis vaccine].
Tian X
Zhonghua Liu Xing Bing Xue Za Zhi; 1993 Jun; 14(3):155-9. PubMed ID: 8221838
[TBL] [Abstract][Full Text] [Related]
67. Immunoglobulin E and G responses to pertussis toxin in children immunised with adsorbed and non-adsorbed whole cell pertussis vaccines.
Duchén K; Granström M; Hedenskog S; Blennow M; Björkstén B
Vaccine; 1997 Oct; 15(14):1558-61. PubMed ID: 9330468
[TBL] [Abstract][Full Text] [Related]
68. High levels of antibody in adults three years after vaccination with a reduced antigen content diphtheria-tetanus-acellular pertussis vaccine.
McIntyre PB; Turnbull FM; Egan AM; Burgess MA; Wolter JM; Schuerman LM
Vaccine; 2004 Dec; 23(3):380-5. PubMed ID: 15530684
[TBL] [Abstract][Full Text] [Related]
69. High prevalence of antibody titers against Bordetella pertussis in an adult population with prolonged cough.
Kapaskelis AM; Vouloumanou EK; Rafailidis PI; Hatzopoulou P; Nikita D; Falagas ME
Respir Med; 2008 Nov; 102(11):1586-91. PubMed ID: 18684605
[TBL] [Abstract][Full Text] [Related]
70. Protection against Bordetella pertussis in mice in the absence of detectable circulating antibody: implications for long-term immunity in children.
Mahon BP; Brady MT; Mills KH
J Infect Dis; 2000 Jun; 181(6):2087-91. PubMed ID: 10837200
[TBL] [Abstract][Full Text] [Related]
71. Seroprevalence of Immunoglobulin G antibodies against pertussis toxin among asymptomatic medical students in the west of Iran: a cross sectional study.
Hashemi SH; Ranjbar M; Hajilooi M; Seif-Rabiei MA; Bolandi M; Moghimi J
BMC Infect Dis; 2009 May; 9():58. PubMed ID: 19426546
[TBL] [Abstract][Full Text] [Related]
72. Pertussis antitoxin decay after vaccination with DTPa. Response to a first booster dose 3 1/2-6 1/2 years after the third vaccine dose.
Hallander HO; Gustafsson L; Ljungman M; Storsaeter J
Vaccine; 2005 Nov; 23(46-47):5359-64. PubMed ID: 16051400
[TBL] [Abstract][Full Text] [Related]
73. Pertussis seroimmunity among mother-infant pairs and infant immune response to pertussis vaccination.
Saffar MJ; Ajami A; Khalilian AR; Qaheri A; Saffar H
Indian Pediatr; 2007 Dec; 44(12):916-8. PubMed ID: 18175845
[TBL] [Abstract][Full Text] [Related]
74. Safety, immunogenicity and an open, retrospective study of efficacy of a monocomponent pertussis toxoid vaccine in infants.
Isacson J; Trollfors B; Taranger J; MacDowall I; Johansson J; Lagergård T; Robbins JB
Pediatr Infect Dis J; 1994 Jan; 13(1):22-7. PubMed ID: 8170728
[TBL] [Abstract][Full Text] [Related]
75. [Humoral reaction to Bordetella pertussis antigens: pertussis toxin, filamentous hemagglutinin and lipopolysaccharide in children with clinical symptoms of whooping cough. I. Antibody level for B pertussis antigens in children without respiratory tract infection symptoms].
Chodorowska M
Med Dosw Mikrobiol; 1999; 51(3-4):259-68. PubMed ID: 10803255
[TBL] [Abstract][Full Text] [Related]
76. Antibody avidity to pertussis toxin after acellular pertussis vaccination and infection.
Knuutila A; Dalby T; Ahvenainen N; Barkoff AM; Jørgensen CS; Fuursted K; Mertsola J; He Q
Emerg Microbes Infect; 2023 Dec; 12(1):e2174782. PubMed ID: 36715361
[TBL] [Abstract][Full Text] [Related]
77. Household contact study of Bordetella pertussis infections.
Deen JL; Mink CA; Cherry JD; Christenson PD; Pineda EF; Lewis K; Blumberg DA; Ross LA
Clin Infect Dis; 1995 Nov; 21(5):1211-9. PubMed ID: 8589145
[TBL] [Abstract][Full Text] [Related]
78. Acellular pertussis vaccines: neutralization by immune sera of the lethality of pertussis toxin and viable Bordetella pertussis for chick embryos.
Calver GA
Biologicals; 1999 Jun; 27(2):143-7. PubMed ID: 10600203
[TBL] [Abstract][Full Text] [Related]
79. Seroprevalence of pertussis antibodies among adolescents in Israel.
Arav-Boger R; Ashkenazi S; Gdalevich M; Cohen D; Danon YL
Isr Med Assoc J; 2000 Feb; 2(2):174-7. PubMed ID: 10804947
[TBL] [Abstract][Full Text] [Related]
80. Verification of components of acellular pertussis vaccines that have been distributed solely, been in routine use for the last two decades and contributed greatly to control of pertussis in Japan.
Kuno-Sakai H; Kimura M; Watanabe H
Biologicals; 2004 Mar; 32(1):29-35. PubMed ID: 15026023
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
